An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Trial Profile

An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2017

At a glance

  • Drugs GSK 3206640A (Primary) ; GSK 3206641A (Primary)
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Sep 2016 Primary endpoint (Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers) has been met according to the results published in the Journal of Infectious Diseases.
    • 07 Sep 2016 Results published in the Journal of Infectious Diseases.
    • 03 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top